Human Insulin Market Set To Expand US$ 46.7 Billion By 2033

Introduction

Global Human Insulin Market size is expected to be worth around US$ 46.7 Billion by 2033 from US$ 29.2 Billion in 2023, growing at a CAGR of 4.8% during the forecast period from 2024 to 2033. In 2023, North America held over 40.7% market share, reaching a revenue total of US$ 11.8 Billion.

The growing prevalence of diabetes globally is driving the adoption of human insulin, contributing significantly to market growth. The rising incidence of diabetes, largely due to sedentary lifestyles, is expected to further boost the insulin market. Additionally, favorable reimbursement policies in developed nations are anticipated to enhance overall market expansion.

The COVID-19 pandemic initially disrupted the demand for insulin as fewer patients sought diabetes treatment. Key market players reported notable revenue declines during this period. Factors such as reduced diabetes testing and limited focus on non-COVID-19 health management led to a drop in insulin sales, particularly in the first half of 2020. This resulted in a 5.5% revenue decline for the insulin market in 2020.

However, the easing of lockdowns and stay-at-home orders in 2021, coupled with the introduction of novel drugs and restoration of supply chain networks, supported market recovery. Novo Nordisk A/S experienced a 4.3% revenue increase for its insulin products compared to 2020. Similarly, Sanofi’s insulin revenue grew by 1.7% in 2021. The resumption of diabetes testing and the launch of new products positively impacted the demand for human insulin during this recovery phase.

Key Takeaways

• Market Size: The Human Insulin Market is projected to reach approximately US$ 46.7 Billion by 2033, up from US$ 29.2 Billion in 2023, indicating substantial growth potential.
• Market Growth: Anticipated growth at a Compound Annual Growth Rate (CAGR) of 4.8% from 2024 to 2033 reflects sustained expansion within the market.
• Type Analysis: Analog Human Insulin holds a significant market share, dominating the segment at 63.5% compared to Traditional Human Insulin.
• Application Analysis: Diabetes Type 1 segment leads the market, accounting for 59.7% market share in 2023, driven by increasing prevalence and daily insulin requirements for blood glucose control.
• Distribution Channel Analysis: Hospital pharmacies play a crucial role, capturing 60.5% market share, emphasizing their importance in ensuring accessibility to insulin products.
• Regional Analysis: North America dominates with 40.7% market share, generating USD 11.8 billion in revenue. However, Asia Pacific is poised for the highest CAGR due to a substantial population at risk of diabetes.
• Drivers: Launch of novel insulin products, rising geriatric population, and increasing demand for insulin are primary factors fueling market growth.
• Restraints: Lack of health funding and diagnosis, particularly in emerging and developing regions, inhibits market growth. Additionally, expensive diagnostics treatments pose challenges, limiting accessibility to insulin.
• Opportunities: Increasing investments in healthcare infrastructure, particularly in emerging economies, present growth opportunities for the human insulin market.
• Trends: Lifestyle factors contributing to the rise in diabetes prevalence, coupled with improvements in research and healthcare facilities, are driving market growth. Furthermore, advancements in insulin delivery devices enhance patient convenience and safety.

Human Insulin Statistics

• Global Diabetes Prevalence: Around 537 million adults aged 20-79 are living with diabetes globally, as per the International Diabetes Federation.
• Type 1 Diabetes in the U.S.: Approximately 1.6 million Americans, including 187,000 children and adolescents, have type 1 diabetes.
• Type 1 Diabetes Worldwide: Globally, about 9 million people depend on daily insulin injections for managing type 1 diabetes.
• Type 2 Diabetes: Over 60 million individuals with type 2 diabetes require insulin for effective disease management.
• Impact of COVID-19: The insulin market experienced a 5.5% revenue decline in 2020 due to reduced diabetes treatments during the pandemic’s initial phase.
• Insulin Price Cap in the U.S.: The Inflation Reduction Act introduced a $35 monthly cap on insulin costs for Medicare beneficiaries starting January 2023, saving seniors an average of $500 annually.
• Price Adjustments by Manufacturers: Companies like Eli Lilly have reduced insulin prices by 70% and capped out-of-pocket expenses at $35 in response to policy changes.
• Affordability Impact: The $35 cap could have saved 1.5 million Medicare beneficiaries approximately $734 million in 2020 if implemented earlier.
• Healthcare Spending on Diabetes: The U.S. spends about $237 billion annually on direct medical expenses related to diabetes.
• Regional Market Leader: North America leads the global insulin market, driven by a high diabetes prevalence and advanced healthcare systems.
• Asia-Pacific Growth: The Asia-Pacific region is projected to have the highest growth rate due to rising diabetes cases and improving healthcare infrastructure.
• California Savings: The cost cap is expected to save 108,000 Medicare beneficiaries in California around $36.6 million annually.
• Market Dominance: Three multinational companies dominate over 90% of the global insulin market, posing challenges for smaller manufacturers.
• Government and WHO Initiatives: Policies, price regulations, and biosimilar insulin promotion are being implemented globally to improve insulin accessibility.
• Technological Advancements: Innovations such as insulin pens and pumps are making insulin delivery more efficient and convenient.
• Global Insulin Consumption: Despite high diabetes prevalence, low- and middle-income countries contribute less than 40% of global insulin sales revenue.

Human Insulin Type Analysis

• Traditional Human Insulin:
  • Short-acting (Regular Insulin): Begins working within 30 minutes, peaks between 2 to 3 hours, and lasts approximately 3 to 6 hours. It’s typically administered 30 minutes before meals to manage postprandial blood glucose levels.
  • Intermediate-acting (NPH Insulin): Starts to work within 2 to 4 hours, peaks between 4 to 12 hours, and has a duration of 12 to 18 hours. It’s often used to control blood sugar levels between meals and overnight.
  • Premixed Insulins: These formulations combine intermediate-acting and short-acting insulins in fixed ratios (e.g., 70% NPH and 30% regular insulin). They provide both basal and prandial glucose control, reducing the number of daily injections.
• Insulin Analogs:
  • Rapid-acting Analogs (e.g., Insulin Lispro, Insulin Aspart, Insulin Glulisine): These insulins begin to work within 15 minutes, peak around 1 hour, and last 2 to 4 hours. They are designed to be taken just before or immediately after meals to control postprandial glucose spikes.
  • Long-acting Analogs (e.g., Insulin Glargine, Insulin Detemir): They have an onset of about 2 hours, minimal or no peak, and provide a steady insulin level lasting up to 24 hours, offering basal glucose control.
  • Ultra-long-acting Analogs (e.g., Insulin Degludec): These insulins start to work within 6 hours, have no pronounced peak, and maintain a stable insulin level for over 36 hours, allowing for flexible dosing schedules.
  • Premixed Analogs: Combining rapid-acting and intermediate-acting analogs, these mixtures offer both immediate and extended glucose control, simplifying insulin regimens for patients.

Emerging Trends in the Insulin Market

• Technological Advancements: Innovations like smart insulin pens and continuous glucose monitoring systems enhance the precision and ease of insulin administration, improving patient outcomes.
• Biosimilar Insulins: The rise in production and approval of biosimilar insulins offers affordable alternatives to branded products, reducing costs for patients and healthcare systems.
• Government Policies: The U.S. Inflation Reduction Act capped monthly insulin costs at $35 for Medicare beneficiaries in 2023, saving seniors an estimated $500 annually.
• Increasing Diabetes Prevalence: With 34.2 million Americans diagnosed with diabetes as of 2023, the growing patient population continues to drive the demand for insulin.
• Focus on Affordability: Efforts to regulate insulin prices and promote biosimilar options are reducing out-of-pocket expenses, making treatments more accessible.
• Global Health Initiatives: The WHO is collaborating with countries and manufacturers to improve insulin availability in low- and middle-income regions through enhanced production and distribution.
• Integration of Digital Health: Mobile apps and telehealth platforms are improving diabetes management and adherence to insulin therapy, enabling better patient engagement.
• Research and Development: New insulin formulations, such as ultra-rapid-acting insulins and those with longer durations of action, are being developed to optimize treatment efficacy.
• Patient Education and Support: Enhanced education and support programs aim to ensure proper insulin usage and adherence, improving quality of life and treatment outcomes.
• Collaborative Efforts: Partnerships between governments, healthcare providers, and pharmaceutical companies are addressing challenges in insulin accessibility and affordability by streamlining supply chains and enhancing distribution networks.

Use Cases of Human Insulin

• Managing Type 1 Diabetes
  • Human insulin is critical for individuals with type 1 diabetes, whose bodies cannot produce insulin. It helps regulate blood glucose levels, preventing life-threatening complications.
  • In the U.S., over 1.6 million people rely on insulin therapy for survival.
• Treating Type 2 Diabetes
  • Insulin is essential for many type 2 diabetes patients when other medications fail to control blood sugar levels. It prevents complications like kidney damage and vision loss.
  • Among the 30 million Americans with diabetes, insulin is vital for managing severe cases.
• Use in Insulin Pumps
  • Insulin pumps deliver continuous doses, offering precise blood sugar control and reducing the need for frequent injections.
  • This method significantly lowers HbA1c levels and enhances the quality of life for users.
• Emergency Situations
  • Rapid-acting insulin is used to treat diabetic ketoacidosis, a severe condition caused by extremely high blood sugar levels, by quickly stabilizing the patient.
  • Approximately 200,000 cases of diabetic ketoacidosis occur annually in the U.S.
• Artificial Pancreas Systems
  • These advanced systems integrate continuous glucose monitoring with insulin pumps to automatically regulate blood sugar, mimicking the function of a healthy pancreas.
  • They improve glucose control while reducing the daily burden of diabetes management.

Conclusion

In conclusion, the human insulin market is poised for substantial growth, driven by the rising global prevalence of diabetes, particularly Type 1 diabetes, and the increasing demand for insulin treatments. Advancements in insulin delivery technologies, along with favorable reimbursement policies and growing investments in healthcare infrastructure, further support market expansion.

While challenges such as high treatment costs and limited accessibility in emerging regions remain, initiatives like biosimilars and government price regulations are expected to alleviate some of these barriers. North America leads the market, but Asia-Pacific is projected to experience the highest growth. Overall, the human insulin market’s future looks promising, with continuous innovation and an increasing focus on affordability and accessibility.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF